New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

David A. Garcia; Renato D. Lopes; Elaine M. Hylek

doi:10.1160/TH10-07-0491

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 104(06): 1099-1105
DOI: 10.1160/TH10-07-0491

Review Article

Schattauer GmbH

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

David A. Garcia

¹Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA

,

Renato D. Lopes

²Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

,

Elaine M. Hylek

³Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

› Institutsangaben

Abstract

Summary

Atrial fibrillation is a common condition that increases the risk of stroke in many patients. Although warfarin has been shown to reduce the risk of stroke, many patients who might benefit from anticoagulation do not receive this therapy. Fear of bleeding is the most often cited reason. Several new anticoagulant medications are being studied to determine their efficacy and safety relative to warfarin. Unlike earlier trials that established the superiority of warfarin over placebo, recent trials in atrial fibrillation have enrolled a disproportionate number of patients already taking warfarin. This review suggests that the risk of both haemorrhage and stroke are highest when atrial fibrillation is newly diagnosed and during the initiation of anticoagulant medication. Randomised controlled trials designed to evaluate the safety and efficacy of new anti-thrombotic agents should include substantial numbers of patients without prior exposure to anticoagulation since these individuals are at the highest risk for bleeding and thromboembolism.

Keywords

Clinical trials - oral anticoagulants - thrombosis - stroke prevention - heart

Volltext

Referenzen

References
1 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study.. J Am Med Assoc 2001; 285: 2370-2375.
2 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 to 2000, and implications on the projections for future prevalence.. Circulation 2006; 114: 119-125.
3 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The framingham study.. Stroke 1991; 22: 983-988.
4 Hart RG, Pearce LA, Miller VT. et al. Cardioembolic vs. Noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.. Cerebrovasc Dis 2000; 10: 39-43.
5 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.. N Engl J Med 2003; 349: 1019-1026.
6 Longstreth Jr WT, Bernick C, Fitzpatrick A. et al. Frequency and predictors of stroke death in 5,888 participants in the cardiovascular health study.. Neurology 2001; 56: 368-375.
7 Miller VT, Pearce LA, Feinberg WM. et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators.. Neurology 1996; 46: 238-240.
8 Sherman DG, Goldman L, Whiting RB. et al. Thromboembolism in patients with atrial fibrillation.. Arch Neurol 1984; 41: 708-710.
9 Stroke prevention in atrial fibrillation study.. Final results.. Circulation 1991; 84: 527-539.
10 Ezekowitz MD, Bridgers SL, James KE. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators.. N Engl J Med 1992; 327: 1406-1412.
11 Petersen P, Boysen G, Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak study.. Lancet 1989; 1: 175-179.
12 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.. N Engl J Med 1990; 323: 1505-1511.
13 EAFT (European Atrial Fibrillation Trial) study group.. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.. Lancet 1993; 342: 1255-1262.
14 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.. Analysis of pooled data from five randomized controlled trials.. Arch Intern Med 1994; 154: 1449-1457.
15 Waldo AL, Becker RC, Tapson VF. et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.. J Am Coll Cardiol 2005; 46: 1729-1736.
16 Cohen N, Almoznino-Sarafian D, Alon I. et al. Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission.. Stroke 2000; 31: 1217-1222.
17 Gage BF, Boechler M, Doggette AL. et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.. Stroke 2000; 31: 822-827.
18 Hylek EM, D’Antonio J, Evans-Molina C. et al. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.. Stroke 2006; 37: 1075-1080.
19 Birman-Deych E, Radford MJ, Nilasena DS. et al. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation.. Stroke 2006; 37: 1070-1074.
20 Johnston JA, Cluxton Jr RJ, Heaton PC. et al. Predictors of warfarin use among ohio medicaid patients with new-onset nonvalvular atrial fibrillation.. Arch Intern Med 2003; 163: 1705-1710.
21 Executive Steering Committee for the SPORTIF III Investigators.. Stroke Prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation.. Lancet 2003; 362: 1691-1698.
22 Albers GW, Diener HC, Frison L. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial.. J Am Med Assoc 2005; 293: 690-698.
23 Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial.. Lancet 2006; 367: 1903-1912.
24 Connolly SJ, Ezekowitz MD, Yusuf S. et al., and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation.. N Engl J Med 2009; 361: 1139-1151.
25 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): A randomised controlled trial.. Lancet 2007; 370: 493-503.
26 Hylek EM, Frison L, Cupples LA. Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts with Atrial Fibrillation: Potential Insights into Risk from a Comparative Analysis of SPORTIF III versus SPORTIF V (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation).. Stroke 2008; 39: 3009-3014.
27 Feinstein AR. Clinical biostatistics. Xi. Sources of ‘chronology bias’ in cohort statistics.. Clin Pharmacol Ther 1971; 12: 864-879.
28 Ray WA. Evaluating medication effects outside of clinical trials: New-user designs.. Am J Epidemiol 2003; 158: 915-920.
29 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy.. Am J Med 1989; 87: 144-152.
30 Douketis JD, Foster GA, Crowther MA. et al. Clinical risk factors and timing of re-current venous thromboembolism during the initial 3 months of anticoagulant therapy.. Arch Intern Med 2000; 160: 3431-3436.
31 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis.. Ann Intern Med 2003; 139: 893-900.
32 Fihn SD, McDonell M, Martin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient follow-up study group.. Ann Intern Med 1993; 118: 511-520.
33 Steffensen FH, Kristensen K, Ejlersen E. et al. Major haemorrhagic complications during oral anticoagulant therapy in a danish population-based cohort.. J Intern Med 1997; 242: 497-503.
34 Mehta RH, Dabbous OH, Granger CB. et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation.. Am J Cardiol 2003; 92: 1031-1036.
35 Lopes RD, Pieper KS, Horton JR. et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.. Heart 2008; 94: 867-873.
36 Lopes RD, Elliott LE, White HD. et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.. Eur Heart J 2009; 30: 2019-2028.
37 DiMarco JP, Flaker G, Waldo AL. et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the atrial fibrillation follow-up investigation of rhythm management (affirm) study.. Am Heart J 2005; 149: 650-656.
38 Lehto M, Snapinn S, Dickstein K. et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: The optimal experience.. Eur Heart J 2005; 26: 350-356.
39 Gitter MJ, Jaeger TM, Petterson TM. et al. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in rochester, minnesota.. Mayo Clinic Proc 1995; 70: 725-733.
40 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The framingham heart study.. J Am Med Assoc 2003; 290: 1049-1056.
41 Manning WJ, Silverman DI, Waksmonski CA. et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation.. Arch Intern Med 1995; 155: 2193-2198.
42 Tsai LM, Chen JH, Lin LJ. et al. Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation.. Am J Cardiol 1997; 80: 897-900.
43 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.. Circulation 2007; 115: 2689-2696.
44 Jones M, McEwan P, Morgan CL. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: A record linkage study in a large british population.. Heart 2005; 91: 472-477.
45 Menzin J, Boulanger L, Hauch O. et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study.. Ann Pharmacother 2005; 39: 446-451.
46 Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Sportif ii: A dose-guiding, tolerability, and safety study.. J Am Coll Cardiol 2003; 41: 1445-1451.
47 White HD, Gruber M, Feyzi J. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from sportif iii and v.. Arch Intern Med 2007; 167: 239-245.